Powered by

Bausch + Lomb Receives 510(k) Clearance From FDA For Vitesse(TM), The First And Only Hypersonic, Open-Port Vitrectomy System

Apr 26, 2017 - PR Newswire

First Major Vitreous Removal Advancement in 40 Years to be Available Through the New Stellaris Elite(TM) Vision Enhancement System

 Valeant Pharmaceuticals International, Inc.'s (NYSE: VRX and TSX: VRX) wholly owned subsidiary, Bausch + Lomb, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Vitesse(TM), the first and only hypersonic  device for vitreous removal,  which uses a novel, single-needle design and a continuously open-port s...